HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $10
Benzinga Newsdesk 2 years ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and raises the price target from $5 to $10.
HC Wainwright & Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and raises the price target from $5 to $10.